- Home
- ORKA vs XPEL Comparison
ORKA vs XPEL Comparison
Compare ORKA & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORKA | XPEL |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORKA | XPEL |
|---|---|---|
| Price | $34.39 | $53.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $49.73 | N/A |
| AVG Volume (30 Days) | ★ 533.1K | 172.6K |
| Earning Date | 03-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.69 |
| Revenue | N/A | ★ $461,460,000.00 |
| Revenue This Year | N/A | $16.20 |
| Revenue Next Year | N/A | $11.28 |
| P/E Ratio | ★ N/A | $32.11 |
| Revenue Growth | N/A | ★ 10.29 |
| 52 Week Low | $5.49 | $24.25 |
| 52 Week High | $36.51 | $55.84 |
Technical Indicators
Market Signals| Indicator | ORKA | XPEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 58.24 |
| Support Level | $25.79 | $51.93 |
| Resistance Level | $36.51 | $55.84 |
| Average True Range (ATR) | 2.07 | 1.89 |
| MACD | 0.59 | -0.21 |
| Stochastic Oscillator | 80.05 | 66.11 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.